Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, a 20-year-old male with tricho-rhino-phalangeal syndrome was found to have a de novo frameshift mutation in the TRPS1 gene, highlighting the challenges in diagnosing this rare disorder.

In this study, docetaxel combined with prednisone significantly extended survival by about 2.5 months in men with hormone-resistant metastatic prostate cancer compared to mitoxantrone plus prednisone, despite the potential for severe adverse effects.

In this experimental study, researchers found that intravitreal injections of up to 100μg of topotecan in rabbits caused no systemic or ocular toxicity, while 200μg doses resulted in localized retinal changes and decreased electroretinography amplitudes near the injection site.

Docetaxel and oxaliplatin are effective and have manageable side effects for recurrent platinum-sensitive ovarian cancer.

This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.

This case report describes a 35-year-old man who developed an atypical DRESS syndrome after taking topiramate for migraine prevention, which resolved with drug withdrawal and symptomatic treatment.

This study suggests that the optimum X-ray energy for microplanar beam radiation therapy to treat deep-seated tumors may range from 100 to 300 keV, based on therapeutic gain and surface dose considerations.

This study found no significant association between the MDR1 C3435T polymorphism and methotrexate responsiveness in rheumatoid arthritis patients.

This study reported that a modified version of Thymosin beta 4, called PEG-rTβ4, demonstrated potential as a treatment for acute myocardial infarction by improving cardiac function and reducing cell death via specific biochemical pathways, suggesting its promise in drug development efforts.

This review discusses the characteristics, prevalence, and treatment challenges of trichotillomania and provides no new clinical findings.

This study found that fractions of Tridax procumbens extract demonstrated significant antioxidant activity, comparable to standard ascorbic acid, in laboratory tests.

This study found that low-dose methotrexate significantly reduced the steroid requirement in subjects with corticosteroid-requiring asthma without altering their clinical status or causing significant complications.

This study details a case of a 20-year-old woman with APECED syndrome and alopecia areata who experienced complete scalp hair regrowth and improved quality of life after nine months of ruxolitinib treatment, highlighting the drug's effectiveness for severe AA linked to AIRE gene mutation.

This article reviews the genetic mutations associated with hypohidrotic ectodermal dysplasia and reports no new clinical results; the authors highlight the roles of EDA gene isoforms and related receptors.

This review highlights the potential of Sacituzumab Tirumotecan, an antibody-drug conjugate, in treating gynecologic cancers, with ongoing Phase III trials indicating a manageable safety profile and future results expected to shed light on its effectiveness in improving survival and response rates.

This study of South Indian patients with autoimmune rheumatic diseases using low-dose methotrexate reported that while mild adverse effects such as hair loss and nausea were common, serious events like cytopenia were less frequent, and folic acid supplementation significantly reduced their prevalence.

This study reports the first case of eyelash elongation and thickening in a patient with hypereosinophilic syndrome taking the Janus kinase inhibitor ruxolitinib.

In this study, ALRV5XR significantly increased hair regrowth in women with androgenetic alopecia or telogen effluvium, with no adverse events reported.

This article reviews different generations of synthetic retinoids for dermatological use, discussing their efficacy and significant side effects, but reports no new clinical results.

This case report highlights a rare instance of severe multi-organ involvement following a single dose of methotrexate for ectopic pregnancy, requiring intensive care but ultimately successfully treated with leucovorin and supportive care.

This research discusses the parallel clinical development of ritlecitinib, an oral Janus kinase 3/tyrosine kinase inhibitor, for treating conditions such as alopecia areata, vitiligo, ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Results are not reported in the abstract.

This review details the preclinical and early clinical activity and side effects of docetaxel, showing its significant effectiveness against various cancers with neutropenia as a major side effect.

This study identified common and unexpected adverse events associated with ritlecitinib in real-world use, providing insights into its safety profile for treating severe alopecia areata.

TEDAR is crucial for skin cell differentiation and barrier formation.

This review discusses methotrexate's use in dermatology and its mechanisms, pharmacokinetics, dosing, side effects, interactions, and emphasizes the need for further research into optimizing therapy and predicting adverse events.

In this study, researchers developed a novel temperature-sensitive biopolymer-based drug delivery system that enhanced the transdermal delivery of ISX9, a neurogenesis inducer, resulting in more effective hair follicle regrowth and signal pathway activation in vivo compared to traditional topical application.

This study found that TPA induces apoptosis in pig renal epithelial cells by affecting cell cycle proteins, and activated ras can prevent this process.

In a single-center study, adolescents with moderate-to-severe alopecia areata treated with ritlecitinib 50 mg daily for 24 weeks showed significant hair regrowth, with 27.3% achieving near-complete regrowth and 45.5% substantial improvement, without serious safety concerns, according to these researchers.

This study suggests that combining tranexamic acid with low-dose oral retinoids may offer moderate to good improvements for lichen plan pigmentosus, although larger trials are needed for confirmation.